Menu
Explore Our Trials
Gateway for Cancer Research is one of the only nonprofits that exclusively funds innovative Phase I and Phase II cancer clinical trials for patients of all ages, regardless of cancer type. At the forefront of research and discovery, these early-phase trials are the first step in evaluating new cancer drugs, treatments, and therapies.
Results 51-56 of 56
Pancreatic Cancer
A Phase 1b/2 Trial of Immunotherapy with Avelumab and Pepinemab as Second Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma
A Phase 1b/2 Trial of Immunotherapy with Avelumab and Pepinemab as Second Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma Summary: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers and an almost uniformly fatal malignancy. Treatment outcomes remain dismal with a 5-year survival of 9%. The incidence of PDAC is increasing and […]
David Linehan, MD
University of Rochester
Pediatric Rare Cancer
Phase 2 study of nivolumab and ipilimumab in children and young adults with relapsed or refractory INI1-negative cancers
Phase 2 study of nivolumab and ipilimumab in children and young adults with relapsed or refractory INI1-negative cancers Summary: INI1 is a tumor suppressor gene and several aggressive pediatric tumor types are characterized by INI1 negativity, including rhabdoid tumors, epithelioid sarcoma, and chordoma. These cancers represent a portion of rare tumor diagnoses and each are […]
Suzanne Forrest, MD
Dana-Farber Cancer Institute
Head/Neck Cancer
Harnessing Innate Immunity in Solid Tumors: CTLA-4 Inhibition in Combination with Memory-like Natural Killer (NK) Cell Immune Cell Therapy in Advanced Head & Neck Cancer
Harnessing Innate Immunity in Solid Tumors: CTLA-4 Inhibition in Combination with Memory-like Natural Killer (NK) Cell Immune Cell Therapy in Advanced Head & Neck Cancer Summary: Outcomes for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) remain quite poor with survival measured in months in most cases. Immunotherapy, specifically […]
Rizwan Romee, MD
Dana-Farber Cancer Institute
Live/Bile Duct
Telemedicine for FGFR focused diagnostics & novel cholangio therapies
Telemedicine for FGFR focused diagnostics & novel cholangio therapies Summary: Cholangiocarcinoma is a rare and aggressive liver cancer affecting the bile duct. Patients with cholangiocarcinoma can benefit from clinical and genetics expertise found at university-based cancer centers. However, most patients cannot travel long distances and pay expensive out-of-pocket costs for this expert level of care. […]
Sameek Roychowdhury, MD, PhD
The Ohio State University
Lung Cancer
Predictive biomarkers for pneumonitis after chemoradiotherapy and immunotherapy in Patients With Non-small Cell Lung Cancer
Predictive biomarkers for pneumonitis after chemoradiotherapy and immunotherapy in Patients With Non-small Cell Lung Cancer Summary: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by producing durable responses. For example, approximately up to 20% of patients with metastatic non-small cell lung cancer (NSCLC) have durable clinical responses. However, this is not without toxicities. Immune-related adverse […]
Ajay Sheshadri, MD, MSCI
MD Anderson Cancer Center
Pediatric Blood Cancer
Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33 CAR T) in Children and Young Adults with Relapsed/Refractory Acute Myeloid Leukemia
Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33 CAR T) in Children and Young Adults with Relapsed/Refractory Acute Myeloid Leukemia Summary: While a first remission is possible for pediatrics patients with acute myeloid leukemia (AML), only 60% will remain in long-term remission despite intensive therapy and allogeneic stem cell transplant (stem cell transplant from a donor). […]
Steven Devine, MD
Be The Match Foundation
